Regulus Therapeutics Inc.
RGLS
Rank in Stocks
#17341
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
-56.96%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)
Category
Healthcare
P/S ratio for Regulus Therapeutics Inc. (RGLS)
P/S ratio as of October 2026 TTM: 10.69
According to Regulus Therapeutics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.69. At the end of 2022 the company had a P/S ratio of 1.64.
P/S ratio history for Regulus Therapeutics Inc. from 2002 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 10.69 | 107.09% |
| 2023 | 5.16 | 214.26% |
| 2022 | 1.64 | -73.36% |
| 2021 | 6.16 | -33.92% |
| 2020 | 9.33 | -83.36% |
| 2019 | 56.03 | 54.87% |
| 2018 | 36.18 | -4.78% |
| 2017 | 38.00 | -28.48% |
| 2016 | 53.12 | 122.76% |
| 2015 | 23.85 | -30.11% |
| 2014 | 34.12 | 41.52% |
| 2013 | 24.11 | -33.67% |
| 2012 | 36.35 | -50.73% |
| 2011 | 73.78 | -9.84% |
| 2010 | 81.83 | 0.48% |
| 2009 | 81.44 | -12.87% |
| 2008 | 93.48 | -5.92% |
| 2007 | 99.36 | -13.68% |
| 2006 | 115.10 | -84.55% |
| 2005 | 745.11 | 242.52% |
| 2004 | 217.54 | -23.37% |
| 2003 | 283.88 | 2.98% |
| 2002 | 275.67 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | -6.21% |
US
|
|
| 40.55 | 279.49% |
US
|
|
| 3.96 | -62.93% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -5.05% |
NL
|
